1659302-89-2
Chemical Structure
EIDD-1723
- CAS No.: 1659302-89-2
- Formula:C22H32NNa2O6P
- Molecular Weight:483.45
IUPAC Name: sodium ((((E)-1-((8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethylidene)amino)oxy)methyl phosphate
InChIKey: SXDGHAWSHQZKQM-ZZSMYOISSA-L
SMILES: C[C@@]12[C@](CC[C@@H]2/C(C)=N/OCOP(O[Na])(O[Na])=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4(C(CC3)=CC(CC4)=O)C
Biological Activity: EIDD-1723 is a Progesterone (HY-N0437) analogues, that binds progesterone receptor (PR) with an IC50 of 2.25 μM. EIDD-1723 is the prodrug of EIDD-036 (HY-17649). EIDD-1723 may exert its neuroprotective effects not solely through progesterone receptor (PR)-dependent pathways but also via non-genomic mechanisms, such as modulation of inflammatory responses and oxidative stress. EIDD-1723 can be used for the study of traumatic brain injury (TBI)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
EIDD-1723 | EIDD-1723 is a Progesterone (HY-N0437) analogues, that binds progesterone receptor (PR) with an IC50 of 2.25 μM. EIDD-1723 is the prodrug of EIDD-036 (HY-17649). EIDD-1723 may exert its neuroprotective effects not solely through progesterone receptor (PR)-dependent pathways but also via non-genomic mechanisms, such as modulation of inflammatory responses and oxidative stress. EIDD-1723 can be used for the study of traumatic brain injury (TBI). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wali B, et al. Evaluating the neurotherapeutic potential of a water-soluble progesterone analog after traumatic brain injury in rats. Neuropharmacology. 2016 Oct;109:148-158. [Content Brief]
- [2]. Fritzemeier RG, et al. Neurotherapeutic Potential of Water-Soluble pH-Responsive Prodrugs of EIDD-036 in Traumatic Brain Injury. J Med Chem. 2023 Apr 27;66(8):5397-5414. [Content Brief]
- [3]. Sayeed I, et al. Development of a novel progesterone analog in the treatment of traumatic brain injury. Neuropharmacology. 2019 Feb;145(Pt B):292-298. [Content Brief]
